refusing hormone therapy for breast cancer

Release time ：Dec-26,2024

Declining hormone therapy for breast cancer can negatively impact a patient's health. Post-surgery, physicians typically suggest hormone therapy based on tumor characteristics to mitigate the risk of cancer reoccurrence. However, some patients might opt out of this treatment due to concerns regarding side effects or personal reasons.

Refusing hormone therapy could result in a higher risk of recurrence. This therapy functions by either blocking estrogen's effects or reducing estrogen levels to curb tumor growth. For patients with hormone receptor-positive breast cancer, it significantly diminishes the likelihood of recurrence. Patients who forgo hormone therapy may face a higher risk of recurrence compared to those who undergo treatment. Additionally, recurrent cancers may be more aggressive and challenging to manage.

Beyond the heightened risk of recurrence, declining hormone therapy might deprive patients of the chance to enhance survival rates. Numerous studies have demonstrated that hormone therapy can boost survival rates for appropriate candidates. Thus, before considering the refusal of hormone therapy, patients should engage in thorough discussions with their healthcare providers to grasp the potential benefits and risks, facilitating informed decision-making.

In conclusion, while the decision to refuse hormone therapy for breast cancer is a personal one, patients should recognize its potential detrimental health effects. Under a physician's guidance, they should consider their medical condition and treatment objectives to make the most appropriate treatment choices. Furthermore, adhering to their doctors' recommendations for regular follow-ups and monitoring is crucial for the timely detection and management of any emerging issues.